BioCryst

YTD

ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

CEO

Charles K. Gayer

CEOCharles K. Gayer

Employees

435

Employees435

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

1986

Founded1986

Employees

435

Employees435

BCRX Key Statistics

Market cap

2.38B

Market cap2.38B

Price-Earnings ratio

-5.13

Price-Earnings ratio-5.13

Dividend yield

—

Dividend yield—

Average volume

4.82M

Average volume4.82M

High today

$9.40

High today$9.40

Low today

$9.12

Low today$9.12

Open price

$9.18

Open price$9.18

Volume

1.40M

Volume1.40M

52 Week high

$11.22

52 Week high$11.22

52 Week low

$6.00

52 Week low$6.00

Stock Snapshot

BioCryst(BCRX) stock is priced at $9.36, giving the company a market capitalization of 2.38B. It carries a P/E multiple of -5.13.

On 2026-07-21, BioCryst(BCRX) stock traded between a low of $9.12 and a high of $9.40. Shares are currently priced at $9.36, which is +2.6% above the low and -0.4% below the high.

BioCryst(BCRX) shares are trading with a volume of 1.4M, against a daily average of 4.82M.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.22 at its peak.

BCRX News

Simply Wall St 1d

Can BioCryst Pharmaceuticals Be Worth More As A New CSO Sharpens Its Pipeline Story?

BioCryst Pharmaceuticals (BCRX) has created a new Chief Scientific Officer role and appointed David W. Jenkins, an industry veteran with broad R&D and external...

TipRanks 6d

BioCryst appoints David Jenkins as chief scientific officer

BioCryst (BCRX) announced the appointment of David Jenkins to the newly created position of chief scientific officer, effective immediately, reporting to Sandee...

Simply Wall St 7d

BioCryst Stock Looks Like A Bargain After Facility Closure

BioCryst Pharmaceuticals stock has rebounded in recent years but is still down about 40.0% over five years, which sits alongside valuation checks that currently...

Analyst ratings

91%

of 11 ratings

Buy

90.9%

Hold

9.1%

Sell

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.